The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications
Open accessAbstract
Conspectus After decades of extensive fundamental studies and clinical trials, lipid nanoparticles (LNPs) have demonstrated effective mRNA delivery such as the Moderna and Pfizer-BioNTech vaccines fighting against COVID-19. Moreover, researchers and clinicians have been investigating mRNA therapeutics for a variety of therapeutic indications including protein replacement therapy, genome editing, and cancer immunotherapy. To realize these therapeutics in the clinic, there are many formidable challenges. First, novel delivery systems such as LNPs with high delivery efficiency and low toxicity need to be developed for different cell types. Second, mRNA molecules need to be engineered for improved pharmaceutical properties. Lastly, the LNP–mRNA nanoparticle formulations need to match their therapeutic applications. In this Account, we summarize our recent advances in the design and development of various classes of lipids and lipid derivatives, which can be formulated with multiple types of mRNA molecules to treat diverse diseases. For example, we conceived a series of ionizable lipid-like molecules based on the structures of a benzene core, an amide linker, and hydrophobic tails. We identified N 1, N 3, N 5 -tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide (TT3) as a lead compound for mRNA delivery both in vitro and in vivo . Moreover, we tuned the biodegradability of these lipid-like molecules by introducing branched ester or linear ester chains. Meanwhile, inspired by biomimetic compounds, we synthesized vitamin-derived lipids, chemotherapeutic conjugated lipids, phospholipids, and glycolipids. These scaffolds greatly broaden the chemical space of ionizable lipids for mRNA delivery. In another section, we highlight our efforts on the research direction of mRNA engineering. We previously optimized mRNA chemistry using chemically-modified nucleotides to increase the protein expression, such as pseudouridine (ψ), 5-methoxyuridine (5moU), and N 1 -methylpseudouridine (me 1 ψ). Also, we engineered the sequences of mRNA 5′ untranslated regions (5′-UTRs) and 3′ untranslated regions (3′-UTRs), which dramatically enhanced protein expression. With the progress of LNP development and mRNA engineering, we consolidate these technologies and apply them to treat diseases such as genetic disorders, infectious diseases, and cancers. For instance, TT3 and its analog-derived lipid-like nanoparticles can effectively deliver factor IX or VIII mRNA and recover the clotting activity in hemophilia mouse models. Engineered mRNAs encoding SARS-CoV-2 antigens serve well as vaccine candidates against COVID-19. Vitamin-derived lipid nanoparticles loaded with antimicrobial peptide-cathepsin B mRNA enable adoptive macrophage transfer to treat multidrug resistant bacterial sepsis. Biomimetic lipids such as phospholipids formulated with mRNAs encoding costimulatory receptors lead to enhanced cancer immunotherapy. Overall, lipid–mRNA nanoparticle formulations have considerably benefited public health in the COVID-19 pandemic. To expand their applications in clinical use, research work from many disciplines such as chemistry, engineering, materials, pharmaceutical sciences, and medicine need to be integrated. With these collaborative efforts, we believe that more and more lipid–mRNA nanoparticle formulations will enter the clinic in the near future and benefit human health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Membrane lipids: where they are and how they behave
van Meer, G., Voelker, D. R., & Feigenson, G. W. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2330 · Cited by 7,157
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Self-citationKnocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Evolution and classification of the CRISPR–Cas systems
Makarova, K. S., Haft, D. H., Barrangou, R., Brouns, S. J. J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F. J. M., Wolf, Y. I., Yakunin, A. F., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2577 · Cited by 2,331
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Recognizing Sepsis as a Global Health Priority — A WHO Resolution
Reinhart, K., Daniels, R., Kissoon, N., Machado, F. R., Schachter, R. D., & Finfer, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1707170 · Cited by 1,356
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis
BRENNER, S., JACOB, F., & MESELSON, M. (1961) · Nature · doi:10.1038/190576a0 · Cited by 1,234
Lipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
mRNA vaccine for cancer immunotherapy
Miao, L., Zhang, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01335-5 · Cited by 934
Self-citationMolecular alterations in triple-negative breast cancer—the road to new treatment strategies
Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32454-0 · Cited by 872
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
Unstable Ribonucleic Acid Revealed by Pulse Labelling of Escherichia Coli
GROS, F., HIATT, H., GILBERT, W., KURLAND, C. G., RISEBROUGH, R. W., & WATSON, J. D. (1961) · Nature · doi:10.1038/190581a0 · Cited by 694
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Self-citationmRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Molecular biology of PCSK9: its role in LDL metabolism
HORTON, J., COHEN, J., & HOBBS, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.12.008 · Cited by 621
Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14527-2 · Cited by 601
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
Lokugamage, M. P., Vanover, D., Beyersdorf, J., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J.-K., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 495
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Dong, Y., Love, K. T., Dorkin, J. R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R. L., Yin, H., Chen, Y., Vegas, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322937111 · Cited by 488
Self-citationCarrasco, M. J., Alishetty, S., Alameh, M.-G., Said, H., Wright, L., Paige, M., Soliman, O., Weissman, D., Cleveland, T. E., Grishaev, A., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02441-2 · Cited by 428
Liu, J., Chang, J., Jiang, Y., Meng, X., Sun, T., Mao, L., Xu, Q., & Wang, M. (2019) · Advanced Materials · doi:10.1002/adma.201902575 · Cited by 373
Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver
Miao, L., Lin, J., Huang, Y., Li, L., Delcassian, D., Ge, Y., Shi, Y., & Anderson, D. G. (2020) · Nature Communications · doi:10.1038/s41467-020-16248-y · Cited by 343
Control of mammalian translation by mRNA structure near caps
Babendure, J. R., Babendure, J. L., Ding, J.-H., & Tsien, R. Y. (2006) · RNA · doi:10.1261/rna.2309906 · Cited by 339
Islam, M. A., Xu, Y., Tao, W., Ubellacker, J. M., Lim, M., Aum, D., Lee, G. Y., Zhou, K., Zope, H., Yu, M., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0284-0 · Cited by 339
Ariga, T., McDonald, M. P., & Yu, R. K. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800007-jlr200 · Cited by 318
Hajj, K. A., Ball, R. L., Deluty, S. B., Singh, S. R., Strelkova, D., Knapp, C. M., & Whitehead, K. A. (2019) · Small · doi:10.1002/smll.201805097 · Cited by 312
Hou, X., Zhang, X., Zhao, W., Zeng, C., Deng, B., McComb, D. W., Du, S., Zhang, C., Li, W., & Dong, Y. (2020) · Nature Nanotechnology · doi:10.1038/s41565-019-0600-1 · Cited by 290
Self-citationChemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Self-citationLong-term storage of lipid-like nanoparticles for mRNA delivery
Zhao, P., Hou, X., Yan, J., Du, S., Xue, Y., Li, W., Xiang, G., & Dong, Y. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.03.001 · Cited by 233
Self-citationIonizable lipid nanoparticles for in utero mRNA delivery
Riley, R. S., Kashyap, M. V., Billingsley, M. M., White, B., Alameh, M.-G., Bose, S. K., Zoltick, P. W., Li, H., Zhang, R., Cheng, A. Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.aba1028 · Cited by 222
Cheng, Q., Wei, T., Jia, Y., Farbiak, L., Zhou, K., Zhang, S., Wei, Y., Zhu, H., & Siegwart, D. J. (2018) · Advanced Materials · doi:10.1002/adma.201805308 · Cited by 221
Ma, F., Yang, L., Sun, Z., Chen, J., Rui, X., Glass, Z., & Xu, Q. (2020) · Science Advances · doi:10.1126/sciadv.abb4429 · Cited by 218
Islam, M. A., Rice, J., Reesor, E., Zope, H., Tao, W., Lim, M., Ding, J., Chen, Y., Aduluso, D., Zetter, B. R., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120431 · Cited by 216
Naturally occurring modified ribonucleosides
McCown, P. J., Ruszkowska, A., Kunkler, C. N., Breger, K., Hulewicz, J. P., Wang, M. C., Springer, N. A., & Brown, J. A. (2020) · WIREs RNA · doi:10.1002/wrna.1595 · Cited by 212
Polymers in Small-Interfering RNA Delivery
Singha, K., Namgung, R., & Kim, W. J. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0293 · Cited by 198
Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing
Zhang, X., Zhao, W., Nguyen, G. N., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc2315 · Cited by 182
Self-citationEffects of Chemically Modified Messenger RNA on Protein Expression
Li, B., Luo, X. L., & Dong, Y. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00090 · Cited by 174
Self-citationAlnylam launches era of RNAi drugs
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt0918-777 · Cited by 157
Leveraging mRNA Sequences and Nanoparticles to Deliver SARS‐CoV‐2 Antigens In Vivo
Zeng, C., Hou, X., Yan, J., Zhang, C., Li, W., Zhao, W., Du, S., & Dong, Y. (2020) · Advanced Materials · doi:10.1002/adma.202004452 · Cited by 152
Self-citationDesigaux, L., Sainlos, M., Lambert, O., Chèvre, R., Letrou-Bonneval, E., Vigneron, J., Lehn, P., Lehn, J., & Pitard, B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707431104 · Cited by 146
Engineering CRISPR–Cpf1 crRNAs and mRNAs to maximize genome editing efficiency
Li, B., Zhao, W., Luo, X. L., Zhang, X., Li, C., Zeng, C., & Dong, Y. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0066 · Cited by 134
Self-citationSemba, R. D. (2012) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000124 · Cited by 126
mRNA: Fulfilling the Promise of Gene Therapy
Weissman, D., & Karikó, K. (2015) · Molecular Therapy · doi:10.1038/mt.2015.138 · Cited by 121
Treatment of hemophilia: a review of current advances and ongoing issues
Coppola, A. (2010) · Journal of Blood Medicine · doi:10.2147/jbm.s6885 · Cited by 119
Systemic delivery of mRNA and DNA to the lung using polymer-lipid nanoparticles
Kaczmarek, J. C., Patel, A. K., Rhym, L. H., Palmiero, U. C., Bhat, B., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120966 · Cited by 114
Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo
Zhang, X., Li, B., Luo, X., Zhao, W., Jiang, J., Zhang, C., Gao, M., Chen, X., & Dong, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b08163 · Cited by 107
Self-citationLipid Polymer Hybrid Nanomaterials for mRNA Delivery
Zhao, W., Zhang, C., Li, B., Zhang, X., Luo, X. L., Zeng, C., Li, W., Gao, M., & Dong, Y. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0536-9 · Cited by 89
Self-citationRNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Self-citationModular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery
van der Meel, R., Chen, S., Zaifman, J., Kulkarni, J. A., Zhang, X. R. S., Tam, Y. K., Bally, M. B., Schiffelers, R. M., Ciufolini, M. A., Cullis, P. R., et al. (2021) · Small · doi:10.1002/smll.202103025 · Cited by 74
Zhang, C., Zhang, X., Zhao, W., Zeng, C., Li, W., Li, B., Luo, X., Li, J., Jiang, J., Deng, B., et al. (2019) · Nano Research · doi:10.1007/s12274-019-2308-9 · Cited by 61
Self-citationDelivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide
Li, Y., Lee, R. J., Yu, K., Bi, Y., Qi, Y., Sun, Y., Li, Y., Xie, J., & Teng, L. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b09991 · Cited by 58
Kawaguchi, D., Kodama, A., Abe, N., Takebuchi, K., Hashiya, F., Tomoike, F., Nakamoto, K., Kimura, Y., Shimizu, Y., & Abe, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202007111 · Cited by 58
Design and assessment of engineered CRISPR–Cpf1 and its use for genome editing
Li, B., Zeng, C., & Dong, Y. (2018) · Nature Protocols · doi:10.1038/nprot.2018.004 · Cited by 52
Self-citationStructurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference
Li, J., Wu, C., Wang, W., He, Y., Elkayam, E., Joshua‐Tor, L., & Hammond, P. T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719565115 · Cited by 45
Russick, J., Delignat, S., Milanov, P., Christophe, O. D., Boros, G., Denis, C. V., Lenting, P. J., Kaveri, S. V., & Lacroix‐Desmazes, S. (2019) · Haematologica · doi:10.3324/haematol.2018.210583 · Cited by 31
Advances of nanomaterials‐based strategies for fighting against COVID‐19
Zeng, C., Hou, X., Bohmer, M., & Dong, Y. (2021) · Open Research (University of Surrey) · doi:10.1002/viw.20200180 · Cited by 21
Self-citationSong, X., Zhang, Y., Sun, H., Dong, P., Zhang, Z., & Liu, J. (2019) · Journal of Nanomaterials · doi:10.1155/2019/9827625 · Cited by 7
Self-citation
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities
Kashyap, B. K., Singh, V. V., Solanki, M. K., Kumar, A., Ruokolainen, J., & Kesari, K. K. (2023) · ACS Omega · doi:10.1021/acsomega.2c07840 · Cited by 348
Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy
You, Y., Tian, Y., Yang, Z., Shi, J., Kwak, K. J., Tong, Y., Estania, A. P., Cao, J., Hsu, W.-H., Liu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00989-w · Cited by 258
Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system
Wang, C., Xue, Y., Markovic, T., Li, H., Wang, S., Zhong, Y., Du, S., Zhang, Y., Hou, X., Yu, Y., et al. (2025) · Nature Materials · doi:10.1038/s41563-024-02114-5 · Cited by 171
Self-citationmRNA lipid nanoparticle formulation, characterization and evaluation
Ma, Y., VanKeulen-Miller, R., & Fenton, O. S. (2025) · Nature Protocols · doi:10.1038/s41596-024-01134-4 · Cited by 54
Metadata
- Authors
- Wang, C., Zhang, Y., & Dong, Y.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-11-18
- Volume
- 54
- Issue
- 23
- Pages
- 4283-4293
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W3214570726
- Cited by
- 265
- References
- 73
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.